ReviewHerz2018
Drug treatment of heart failure in the elderly.
Review in Herz, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Clinical Trials in Older Adults with Cardiovascular Multimorbidity: A Perspective on Pragmatic Trial Design.Journal of clinical medicine · 2026Article
- Heart Failure in Elderly Patients: Medical Management, Therapies and Biomarkers.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Characterisation of the octogenarians presenting to the diagnostic heart failure clinic: SHEAF registry.Open heart · 2024Article
- In need of age-appropriate cardiac models: Impact of cell age on extracellular matrix therapy outcomes.Aging cell · 2023Article
- The Use of Brain Natriuretic Peptide in the Evaluation of Heart Failure in Geriatric Patients.Diagnostics (Basel, Switzerland) · 2023Review
- An exploration of the experience of dapagliflozin in clinical practice.Future science OA · 2022Article
- Heart failure in the elderly.Journal of geriatric cardiology : JGC · 2021Article
- Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.Diabetes, obesity & metabolism · 2021Article
- Article
- Drug therapy in elderly heart failure patients.European heart journal supplements : journal of the European Society of Cardiology · 2019Article
- Improved outcome with standardized plan for clinical management of acute decompensated chronic heart failure.Journal of geriatric cardiology : JGC · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prevalence of heart failure increases with age. Changes in the age distribution and growing life expectancy will lead to a further rise. However, data concerning drug treatment of heart failure especially in the elderly are scarce. Subgroup analyses of the heart failure trials suggest that drug therapy in older patients should follow the recommendations in the current guidelines. In doing so, several common comorbidities in these patients (e. g., impaired renal function) have to be considered and may have an influence on the therapy (e. g., drug dose, choice of active pharmaceutical ingredient, etc.). Especially in old, multimorbid patients, possible interaction of drugs might play a substantial role. In many cases the main goal of the therapy, especially in the very elderly, is to improve symptoms and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.